These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

113 related items for PubMed ID: 8383627

  • 1. Natural killer cell activity and progression-free survival in ovarian cancer.
    Garzetti GG, Cignitti M, Ciavattini A, Fabris N, Romanini C.
    Gynecol Obstet Invest; 1993; 35(2):118-20. PubMed ID: 8383627
    [Abstract] [Full Text] [Related]

  • 2. The effect of cimetidine on natural killer activity of peripheral blood lymphocytes of patients with ovarian carcinoma.
    Kikuchi Y, Oomori K, Kizawa I, Kato K.
    Jpn J Clin Oncol; 1985 Jun; 15(2):377-83. PubMed ID: 3839542
    [Abstract] [Full Text] [Related]

  • 3. An assessment of sequential measurements of immune complex levels in ovarian cancer patients with respect to clinical progress.
    Mooney NA, Townsend PA, Wiltshaw E, Evans DG, Shanti-Raju K, Poulton TA.
    Gynecol Oncol; 1983 Apr; 15(2):207-13. PubMed ID: 6299906
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Randomised comparison of cisplatin with cyclophosphamide/cisplatin and with cyclophosphamide/doxorubicin/cisplatin in advanced ovarian cancer. Gruppo Interegionale Cooperativo Oncologico Ginecologia.
    Lancet; 1987 Aug 15; 2(8555):353-9. PubMed ID: 2886821
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Adjuvant platinum-based chemotherapy in patients with epithelial ovarian cancer: prognostic factors and final outcome.
    Grivas A, Lianos E, Internos I, Papaxoinis G, Tselepatiotis E, Ziras N, Athanasiou AE.
    J BUON; 2010 Aug 15; 15(4):647-51. PubMed ID: 21229624
    [Abstract] [Full Text] [Related]

  • 9. Cellular immunologic responsiveness to extracts of ovarian epithelial tumors.
    Melnick H, Barber HR.
    Gynecol Oncol; 1975 Mar 15; 3(1):77-86. PubMed ID: 168133
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Cisplatin-based polychemotherapy reduces the natural cytotoxicity of peripheral blood mononuclear cells in patients with advanced ovarian carcinoma and their in vitro responsiveness to interleukin-12 incubation.
    Garzetti GG, Ciavattini A, Muzzioli M, Romanini C.
    Cancer; 1999 May 15; 85(10):2226-31. PubMed ID: 10326702
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Endometrioid carcinoma of the ovary. Retrospective study.
    Garzetti GG, Ciavattini A, Goteri G, De Nictolis M, Cignitti M, Tranquilli AL, Romanini C.
    Eur J Gynaecol Oncol; 1993 May 15; 14(1):51-5. PubMed ID: 8472733
    [Abstract] [Full Text] [Related]

  • 14. The role of secondary cytoreductive surgery for recurrent mucinous epithelial ovarian cancer (mEOC).
    Cheng X, Jiang R, Li ZT, Tang J, Cai SM, Zhang ZY, Tian WJ, Zang RY.
    Eur J Surg Oncol; 2009 Oct 15; 35(10):1105-8. PubMed ID: 19443175
    [Abstract] [Full Text] [Related]

  • 15. Doxorubicin and cyclophosphamide, alternated with bleomycin and mitomycin C as a second-line regimen in advanced ovarian carcinoma resistant to cisplatin-based chemotherapy.
    Benedetti Panici P, Scambia G, Greggi S, Salerno G, Cento R, Mancuso S.
    Oncology; 1990 Oct 15; 47(4):296-8. PubMed ID: 1694980
    [Abstract] [Full Text] [Related]

  • 16. For women receiving chemotherapy for clinically apparent early ovarian cancer, is there a benefit to surgical staging?
    Dizon DS, Restivo A, Lomme M, Charbonneau N, Brard L, Hughes T, Weitzen S, Legare R, Granai CO, Disilvestro P.
    Am J Clin Oncol; 2008 Feb 15; 31(1):39-42. PubMed ID: 18376226
    [Abstract] [Full Text] [Related]

  • 17. Polychemotherapy in ovarian cancer: treatment with Adriamycin, BCNU and cyclophosphamide vs. Adriamycin and cyclophosphamide.
    Mazzei T, Bonazza M, Amunni G, Scarselli G, Branconi F, Massi GB.
    Chemioterapia; 1984 Feb 15; 3(1):10-5. PubMed ID: 6535650
    [Abstract] [Full Text] [Related]

  • 18. Impact of complete cytoreduction leaving no gross residual disease associated with radical cytoreductive surgical procedures on survival in advanced ovarian cancer.
    Chang SJ, Bristow RE, Ryu HS.
    Ann Surg Oncol; 2012 Dec 15; 19(13):4059-67. PubMed ID: 22766983
    [Abstract] [Full Text] [Related]

  • 19. Epithelial ovarian cancer treated by platinum or platinum analogue with cyclophosphamide: experience in Ramathibodi Hospital.
    Linasmita V, Wilailak S, Srisupundit S, Tangtrakul S, Bullangpoti S, Israngura N.
    J Med Assoc Thai; 1998 Jan 15; 81(1):10-6. PubMed ID: 9470316
    [Abstract] [Full Text] [Related]

  • 20. [Clinical studies on malignant ovarian tumor--with special reference to therapy and prognosis of epithelial ovarian tumor].
    Iwasawa H, Sekiya S, Kaihou T, Takamizawa H.
    Nihon Sanka Fujinka Gakkai Zasshi; 1984 Apr 15; 36(4):525-30. PubMed ID: 6325559
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.